March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.
The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.